I get a kick out of posters here and on other foru
Post# of 72447
(Total Views: 303)
Posted On: 09/08/2018 3:57:03 PM
I get a kick out of posters here and on other forums who paint IPIX as a totally unknown product, acting as though our successful clinical trials mean nothing, and thus we can only expect pennies on the dollar for the drugs in our current pipeline.
Celgene got burned on a Crohn's Disease drug failing P3 trial. Not sure if it was for efficacy or safety. Now look at Brilacidin, safety appears pretty darn good to great and the pictures alone for UC/UCS efficacy cannot be questioned. Combine this with a pill delivery system that should be able to accurately attack at just the right point in the GI tract to maximize efficacy and looks like a pretty good bet to reach commercialization. 100% sure, no, but nothing is in biotech, but far and away better than 99% of anything coming down the pike.
As to Prurisol, Pfizer paid $5.2B for an eczema drug hopeful. Assume we get wonderful results for P2b, then whoever we choose to partner this indication (psoriasis), and assuming they get first choice at other Prurisol indications, will have first shot at a potential great drug for eczema as well as other indications in the dermatology arena as well as all the other diseases in the autoimmune arena. Now being logical, what sort of price would that make one think Prurisol is worth? IMO, more than a measly billion or two. I don't give a rats butt what our current share price is, the potential of P, once excellent P2b results are announced, makes whatever the partners paid nearly a sure bet to result in a big return and all the other possible indications thus become multi-billion dollar bonuses. Note: this all is based on P2b results being very safe, efficacious, and patient quality of life answers being extremely positive.
I like our chances, big time.
Celgene got burned on a Crohn's Disease drug failing P3 trial. Not sure if it was for efficacy or safety. Now look at Brilacidin, safety appears pretty darn good to great and the pictures alone for UC/UCS efficacy cannot be questioned. Combine this with a pill delivery system that should be able to accurately attack at just the right point in the GI tract to maximize efficacy and looks like a pretty good bet to reach commercialization. 100% sure, no, but nothing is in biotech, but far and away better than 99% of anything coming down the pike.
As to Prurisol, Pfizer paid $5.2B for an eczema drug hopeful. Assume we get wonderful results for P2b, then whoever we choose to partner this indication (psoriasis), and assuming they get first choice at other Prurisol indications, will have first shot at a potential great drug for eczema as well as other indications in the dermatology arena as well as all the other diseases in the autoimmune arena. Now being logical, what sort of price would that make one think Prurisol is worth? IMO, more than a measly billion or two. I don't give a rats butt what our current share price is, the potential of P, once excellent P2b results are announced, makes whatever the partners paid nearly a sure bet to result in a big return and all the other possible indications thus become multi-billion dollar bonuses. Note: this all is based on P2b results being very safe, efficacious, and patient quality of life answers being extremely positive.
I like our chances, big time.
(5)
(0)